We have placed cookies on your computer to help make this website better. We use a PIWIK Analytics script which sets performance cookies. More details and information can be found in our cookie policy. Please refer to the privacy statement to adjust your settings for the website analytics tracking by PIWIK (e.g. deny use/opt-out). More info.

Confirm

Where we come from

Although firmly rooted in Germany, today we are very much a growing global business. An integrated research and development company, we have an enviable track record of bringing effective pain treatments and state-of-the-art technologies to patients. Our high level of investment in R&D is testament to our unwavering commitment to innovation.

1947 Penicillin

Grünenthal is the first company in Germany to register penicillin after World War II

1977 Tramal®

Tramal® is launched; it has since become one of the most frequently prescribed central acting analgesics worldwide

2001 Transtec®

Transtec®, an analgesic for chronic pain, is launched in Europe. The innovative transdermal patch with a polymer-based matrix system allows the patient to easily and safely handle

2003 Zaldiar®

Zaldiar® the first fixed-dose analgesic containing paracetamol and a small dose of tramadol used for the treatment of acute pain is launched globally

2007 Versatis®

Versatis® is launched in the EU, a topically acting lidocaine patch used for the treatment of neuropathic pain after herpes zoster

2014 Arcoxia®

We begin to distribute Arcoxia® in several European countries and start to offer an innovative therapy for the treatment of pain with an inflammatory component

2016 Zurampic™

We enter into a licensing agreement with AstraZeneca for the exclusive rights to Zurampic™ (lesinurad) in Europe and Latin America building on our portfolio in the area of inflammatory and pain-related diseases with high unmet need

2017 Zomig®

We enter into an agreement with AstraZeneca for the global rights to Zomig® (Zolmitriptan), excluding Japan, a treatment used for the acute treatment of migraines and cluster headaches. This adds
another major pain indication to our portfolio

2017 Adhesys Medical

We acquire Adhesys Medical GmbH and its US-based affiliate Adhesys Medical Inc., a medical device startup company focused on the development of in-surgery adhesives, expanding our pipeline of medical devices for business with surgeons

Thalidomide

Thalidomide will always be a significant part of our company history.
... contergan.grunenthal.info